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Abstract
 
The differentiation of antigen-stimulated naive CD4 T cells into T helper (Th)1 or Th2 effec-
tor cells can be prevented in vitro by transforming growth factor (TGF)-
 
 
 
 and anti–interferon
(IFN)-
 
 
 
. These cells proliferate and synthesize interleukin (IL)-2 but not IFN-
 
 
 
 or IL-4, and
can differentiate into either Th1 or Th2 cells. We have now used two-color Elispots to reveal
substantial numbers of primed cells producing IL-2 but not IL-4 or IFN-
 
 
 
 during the Th1- or
Th2-biased immune responses induced by soluble proteins or with adjuvants. These cells were
CD4
 
 
 
CD44
 
high
 
 and were present during immediate and long-term immune responses of nor-
mal mice. Naive T cell receptor for antigen (TCR) transgenic (DO11.10) T cells were primed
in vivo after adoptive transfer into normal hosts and FACS
 
®
 
 cloned under conditions that did
not allow further differentiation. After clonal proliferation, aliquots of each clone were cultured
in Th1- or Th2-inducing conditions. Many in vivo–primed cells were uncommitted, secreting
IL-2 but not IL-4 or IFN-
 
 
 
 at the first cloning step, but secreting either IL-4 or IFN-
 
 
 
 after
differentiation in the appropriate conditions. These in vivo-primed, uncommitted, IL-2–pro-
ducing cells may constitute an expanded pool of antigen-specific cells that provide extra flexi-
bility for immune responses by differentiating into Th1 or Th2 phenotypes later during the
same or subsequent immune responses.
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mice • cytokine • immunization
 
Introduction
 
CD4
 
 
 
 T cells regulate immune responses by producing
various cytokines upon antigen stimulation. Naive CD4
 
 
 
 T
cells have limited cytokine responses and secrete only IL-2
before they differentiate into various effector cell types (1–
4). In vitro, naive T cells stimulated with antigen in the
presence of IL-4 differentiate into Th2 cells secreting IL-4,
IL-5, IL-10, and IL-13, whereas IL-12 induces the differ-
entiation of naive cells into Th1 cells secreting IL-2, IFN-
 
 
 
,
and lymphotoxin (5). The choice between Th1 and Th2
responses in vivo can determine the outcome of infections.
Th1 cells assist in activating macrophages and CD8
 
 
 
 T
cells, which are particularly useful for eliminating intracel-
lular infections; Th2 cells mediate antihelminth and allergic
responses (6, 7).
However, the existence of additional cytokine-secreting
T cell effector phenotypes has been suggested by several
studies using single-cell analysis methods, including intra-
cellular staining (8–10), reverse transcription PCR (11), in
situ hybridization (4), and two-color Elispot assays (12).
Although the cytokines expressed by one cell on one oc-
casion may not reflect the full cytokine secretion potential
of the cell (4, 12), several lines of evidence confirm the
existence of additional cytokine secretion patterns. Th0
clones secrete both Th1 and Th2 cytokines (2, 13–15).
Regulatory T cells secreting TGF-
 
  
 
or IL-10 but not IL-4
have been derived from orally tolerized mice (16), or by in
vitro culture of mouse and human T cells in the presence
of IL-10 (17).
We have previously identified primed T cells producing
IL-2 but not IL-4 or IFN-
 
 
 
 during in vitro studies in
which TGF-
 
 
 
 and anti–IFN-
 
 
 
 were added to prevent T
cell differentiation into Th2 or Th1 cells, respectively (18,
19). Although these proliferating precursor T cells (called
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Thpp cells; reference 19) retained the cytokine secretion
pattern of naive cells, they proliferated strongly in response
to antigen. Cloning experiments showed that individual
IL-2–secreting T cells retained the potential to differentiate
into Th2 cells (20) or either Th1 or Th2 cells under appro-
priate conditions (18). A similar mouse T cell population
primed in vitro by brief TCR stimulation secreted only IL-2,
and preferentially migrated to LNs when transferred into
mice (21). These cells acquired effector function more rap-
idly than naive T cells and had a lower activation threshold.
Thus T cells previously activated by antigen in vitro can re-
tain a cytokine secretion phenotype similar to that of naive
cells, i.e., the secretion of IL-2 but not IL-4 or IFN-
 
 
 
.
Primed cells producing mainly IL-2 may also be present
in vivo in both mice and humans. Mouse memory T cells
secreted high levels of IL-2 and low levels of IL-4 or IFN-
 
 
 
when restimulated in vitro (22), and a higher frequency
of cells from lymphoid tissues synthesized IL-2 compared
with IFN-
 
  
 
(23). Human T cells expressing high levels
of the chemokine receptor CCR7 and low levels of
CD45RA mostly expressed IL-2 but not IFN-
 
 
 
, IL-4, or
IL-5 when restimulated, in contrast to the high numbers of
CCR7
 
 
 
CD45RA
 
  
 
T cells expressing all four cytokines
(24). The CCR7
 
 
 
CD45RA
 
 
 
 population (called central
memory cells) included precursors of IFN-
 
 
 
– and IL-4–
secreting cells, although it was not determined whether
precursors were uncommitted or separate precursors were
present in the CCR7
 
 
 
 population.
We have now investigated the cytokine secretion pro-
files and differentiation potential of individual mouse CD4
T cells after in vivo immunization. The frequency of each
cytokine-secreting cell phenotype was determined imme-
diately ex vivo by restimulating cells with antigen plus
APCS and measuring cytokine production by one- and
two-color Elispot. In either Th1-polarized or Th2-polar-
ized responses, many antigen-specific cells detected by
Elispot secreted IL-2 but not IL-4 or IFN-
 
 
 
. Primed IL-2–
secreting cells expressed high levels of CD44 and could be
detected for at least 50 d. To analyze the differentiation po-
tential of in vivo–primed CD4 T cells, TCR transgenic
DO11.10 C
 
 
 
 
 
/
 
 
 
 CD4 T cells were primed in vivo in
an adoptive host and cloned by FACS
 
®
 
. Clone splitting
showed that many cells that initially secreted only IL-2
could subsequently differentiate into either IFN-
 
 
 
– or IL-
4–producing cells, demonstrating that a significant number
of CD4 T cells remain uncommitted when primed during
an in vivo immune response.
 
Materials and Methods
 
Mice.
 
Female C57BL/6 were obtained from The Jackson
Laboratory. Female Balb/c mice, 6–8 wk old, were obtained
from Taconic. Normal female Balb/c mice, 6–8 wk old, carrying
the TCR transgene DO11.10, and homozygous for the TCR
C
 
 
 
 deletion, were provided by Daniela Metz, University of
Rochester, Rochester, NY.
 
Antibodies and Cell Lines.
 
Purified rat anti–mouse IL-2 (JES6-
1A12) antibodies and biotinylated rat anti–mouse IL-2 (JES6-
5H4), IL-4 (BVD6-24G2), and IFN-
 
 
 
 (XMG1.2) antibodies
were obtained from BD PharMingen. Rat anti–mouse IL-4 and
IFN-
 
 
 
 antibodies were purified on a protein G column (Amer-
sham Pharmacia Biotech) from the supernatants of 11B11 (25),
XMG1.2 (26), and AN18 (27) hybridoma cell lines. The follow-
ing PE-, cychrome-, FITC-, and biotin-conjugated antibodies
were purchased from BD PharMingen: anti-CD25 (PC61), anti-
CD4 (RM4-5), anti-CD44 (IM7), anti-NK1.1 (NKR-P1C),
anti-CD45R/B220 (RA3-6B2), anti-CD8 (53-6.7), and anti-
CD62L (Mel-14).
 
Immunization and Cell Preparation.
 
C57BL/6 mice were im-
munized intraperitoneally with 2.5 or 80 
 
 
 
g KLH (Calbiochem)
in 50 
 
 
 
l of PBS; or KLH (2.5 
 
 
 
g in 50 
 
 
 
l PBS) plus 50 
 
 
 
l Ribi
adjuvant (Ribi ImmunoChem Research, Inc.). C57Bl/6 mice
were also immunized subcutaneously in the neck with KLH (5
 
 
 
g in 50 
 
 
 
l PBS) plus 50 
 
 
 
l CFA. After 7 or 10 d of immuniza-
tion, cells from spleen, axillary LNs (ALNs)
 
*
 
, popliteal LNs, or
mesenteric LNs (MLNs) were prepared for Elispot analysis. For
enrichment of CD4
 
 
 
 T cells, C57BL/6 spleen cells were incu-
bated with streptavidin-Dynabeads (Dynal) coated with biotin-
conjugated anti-NK1.1, -B220, and -CD8 antibodies. In some
experiments, CD4
 
 
 
 T cells were further purified by sorting on a
cell sorter (EPICS Elite; Beckman Coulter) after staining the cells
with rat anti–mouse CD4-cychrome, CD44-FITC, and CD25-
PE. For CD4
 
 
 
 T cell depletion, whole spleen cells were incu-
bated with streptavidin-Dynabeads coated with biotin-conjugated
rat anti–mouse CD4.
 
Elispot Assay.
 
96-well plates with a nitrocellulose filter base
(Millititer HA; Millipore) were coated with purified anti–IL-2 (2
 
 
 
g/ml), anti–IL-4 (2 
 
 
 
g/ml), or anti–IFN-
 
 
 
 (2 
 
 
 
g/ml) antibod-
ies. After 2 h of incubation at room temperature, the plates were
washed three times with RPMI 1640 medium containing 50 
 
 
 
M
2-mercaptoethanol (Sigma-Aldrich) and 8% FCS (Hyclone Labo-
ratories Ltd. Hornby). Unseparated spleen cells from immunized
mice were added to the plates in doubling dilutions from 5 
 
  
 
10
 
5
 
cells per well in the presence of 80 
 
 
 
g/ml KLH (or as specified in
Figure legends) or 5
 
  
 
g/ml ConA (Amersham Pharmacia Bio-
tech) for restimulation. Spleen cells from a pool of 2–3 normal
mice were added to provide additional APCs, so that all wells
contained 5
 
   
 
10
 
5
 
 total spleen cells. For experiments using sorted
T cell populations, the first wells in the dilution series contained
1–7
 
   
 
10
 
4
 
 sorted cells, and all wells contained 5
 
   
 
10
 
5
 
 spleen cells
from unimmunized mice as APCs. After overnight incubation in
a 37
 
 
 
C CO
 
2
 
 incubator, the plates were washed with PBS with
0.1% Tween (Sigma-Aldrich), and then incubated with biotiny-
lated anti–IL-2 (2 
 
 
 
g/ml), IL-4 (2 
 
 
 
g/ml), or IFN-
 
 
 
 (2 
 
 
 
g/ml)
antibodies in PBS plus 0.1% Tween 20 plus 2% BSA (PBSTB),
followed by streptavidin-horseradish peroxidase conjugate (SA-
HRP; Jackson ImmunoResearch Laboratories) at 1:1,000 in PB-
STB, and the AEC substrate kit (Vector Laboratories). The plates
were then dried and the filters were removed from the plastic
plate by adhesion to thermowell sealers (Costar). The red spots
were enumerated using a dissecting microscope. In some experi-
ments (e.g., see Fig. 4), the accuracy of the counting was con-
firmed by blind counting by another person, and by automated
computer counting (Zellnet Consulting, Inc.). Identical conclu-
sions were obtained in each case from all counting methods.
For two-color Elispot assays, the plates were coated with puri-
fied anti–IL-2, anti–IL-4, and/or anti–IFN-
 
  
 
antibodies. Cell
 
*
 
Abbreviations used in this paper: 
 
ALN, axillary LN; LDA, limiting dilution
analysis; MLN, mesenteric LN. 
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culture was set up as before. After overnight incubation, biotiny-
lated anti–IL-2 antibodies were first added to the plates followed
by streptavidin-alkaline phosphatase (SA-AP; Jackson Immu-
noResearch Laboratories). The plates were then incubated with
RPMI 1640 as a source of free biotin (10 
 
 
 
g/ml) to block the
free binding sites of the streptavidin. After 30-min incubation at
room temperature, biotinylated anti–IL-4 and/or anti–IFN-
 
 
 
 an-
tibodies were added to the plates followed by SA-HRP. The
plates were then incubated with the peroxidase substrate AEC
and the phosphatase substrate BCIP/NBT (Biomeda Corp.) se-
quentially to develop the red and blue color spots. In some ex-
periments, IL-2–producing cells were detected as red spots and
IL-4– and/or IFN-
 
 
 
–producing cells were detected as blue spots.
 
Elispot Calculations.
 
In two-color Elispot assays, the blue
color was dominant, and so in some experiments it was difficult
to distinguish blue spots from blue-red spots. Red spots could be
counted directly, but comparison of multiple calculations was
necessary to reliably enumerate blue and blue-red spots.
In experiments using both single and two-color Elispot assays,
the spots were enumerated in the following categories: single-
color assays: Bs, Blue (IL-2); Rs, Red (IL-4); and double-color
assay: Bd, Blue (IL-2); Rd, Red (IL-4); BR, Blue-Red (IL-2 plus
IL-4). From these properties, the number of cells secreting IL-2
and/or IL-4 were calculated as follows: cells secreting IL-4 but
not IL-2: Rd; cells secreting IL-2 and IL-4: BR or Rs-Rd; and
cells secreting IL-2 but not IL-4: Bd or Bs-(Rs-Rd) or Bs-BR.
 
Limiting Dilution Cloning.
 
Spleen cells from mice immunized
7 d previously with KLH plus Ribi were centrifuged in Lym-
pholyte-M (Cedarlane Laboratories) to remove RBCs. Lympho-
cytes were stained with cychrome-anti-CD4 (20 ng/million lym-
phocytes) and FITC-anti-CD44 (50 ng/million lymphocytes).
CD4
 
 
 
CD44
 
high
 
 cells were sorted on a FACS Vantage™ SE sorter
(BD PharMingen). Sorted cells were titrated from 2,000 to 0 cells
per well and were put into 96-well plate in the following condi-
tions: 2 ng/ml IL-2 (28), 2 ng/ml IL-7 (BD PharMingen), 3%
MLR supernatant, 100 
 
 
 
g/ml KLH, 40 
 
 
 
g/ml XMG1.2, 10 
 
 
 
g/
ml 11B11, 1 ng/ml TGF-
 
 
 
 (GIBCO BRL), and 4
 
   
 
10
 
5
 
 irradi-
ated whole spleen cells. After 6 d, positive growing wells were
picked and split into Th1 conditions with IL-2, IL-7, KLH, IL-
12 (0.1% Cos transfection supernatant), and 11B11, or Th2 con-
ditions with IL-2, IL-7, KLH, IL-4 (a gift from Schering Plough,
2 ng/ml), and XMG1.2 for another 4 d. Cells were then washed
and rested in medium with only 1 ng/ml IL-2. 2 d later, they
were restimulated with 100 
 
 
 
g/ml KLH and APCs (5
 
   
 
10
 
5
 
 cells
per well) in Elispot assay to measure IL-2–, IL-4–, and IFN-
 
 
 
–
producing cell frequencies.
 
Single Cell Cloning and Split Culturing of In Vivo–primed
DO11.10 C
 
 
 
 
 
/
 
 
 
CD4 T Cells.
 
Cells from LNs and spleens of
naive DO11.10 C
 
 
 
 
 
/
 
 
 
 
 
mice were adoptively transferred by intra-
peritoneal injection of 10
 
7
 
 lymphocytes into naive Balb/c mice. 1 d
later the host mice were immunized subcutaneously in the neck
with 25 
 
 
 
g of OVA peptide
 
323–339 
 
(P
 
OVA
 
, provided by Daniela
Metz) in 50 
 
 
 
l PBS plus 50 
 
 
 
l Ribi adjuvant. 6 d later, ALN cells
were stained with cychrome-anti-CD4, biotinylated-KJ1-26
(provided by Daniela Metz), and PE-anti-CD62L antibodies.
Single CD4
 
 
 
KJ1-26
 
 
 
CD62L
 
low
 
 lymphocytes were deposited into
each well of 96-well plates with the Autoclone attachment on the
Coulter Epics Elite FACS
 
®
 
. Sorted cells were stimulated with
peptide (2 
 
 
 
g/ml) and APCs (TA3 cells, 10
 
4
 
 cells per well) in the
presence of 1 ng/ml human IL-2 (Chiron), mouse IL-7, 40 
 
 
 
g/
ml 11B11, 50 
 
 
 
g/ml XMG1.2, and 1 ng/ml TGF-
 
 
 
. After 7–10 d
of culture, the growing clones were split into two aliquots
which were restimulated with peptide, APCs, human IL-2, and
mouse IL-7 in either Th1 conditions (IL-12 and 11B11) or Th2
conditions (IL-4 and XMG1.2).
 
Results
 
KLH Immunization Induced IL-2 and IL-4 Responses.
 
We previously defined in vitro a population of CD4
 
  T
cells that proliferate in the presence of TGF-  and anti–
IFN-  antibody without differentiating into Th2 or Th1
subsets. These cells secrete IL-2 but not IL-4, IL-5, or
IFN-  when restimulated, and have the potential to further
differentiate into Th1 and Th2 subsets under appropriate
polarizing conditions (18). To look for in vivo evidence of
these primed IL-2–producing cells, we immunized mice
with a small amount of KLH, without adjuvant. 7 d after in
vivo immunization, spleen cells were stimulated directly ex
vivo with antigen plus APCs, and the numbers of cells se-
creting IL-2, IL-4, or IFN-  were measured by Elispot.
Substantial numbers of well-defined IL-2 Elispots were
produced by cells from mice immunized with KLH (Fig. 1
a and d) but not from unimmunized mice. The in vitro re-
sponse was KLH-specific (e.g., Fig. 1 d vs. g).
In addition to the IL-2 Elispots, KLH-specific IL-4
Elispots were also detected, but at a lower frequency (Fig. 1
b, e, and h). However, no KLH-specific IFN- –secreting
cells were detected (Fig. 1 c and f), although ConA in-
duced high numbers of IFN- –secreting cells in the same
experiment (Fig. 1 i), confirming that the IFN-  Elispot as-
say was effective. Thus, immunization of mice with a small
amount of KLH resulted in a population of antigen-specific
T cells that secreted IL-2 and/or IL-4, but not IFN- 
when restimulated in vitro. The primed, IL-2–secreting
cells were unlikely to be Th1 cells because there was no
KLH-specific IFN-  response, and the higher number of
IL-2–secreting cells suggested that at least some primed IL-
2–secreting cells did not secrete IL-4.
Many KLH-specific Spleen Cells Secreted IL-2 but not IL-4
when Restimulated. To demonstrate directly that some
cells secreted IL-2 but not IL-4, we modified a two-color
Elispot method to simultaneously identify IL-2 and IL-4
producers. Spleen cells from mice immunized 7 d previ-
ously with KLH were restimulated in vitro with antigen
and analyzed by cytokine Elispot for cells secreting IL-2
(blue) and/or IL-4 (red). Three Elispot assays were carried
out for each sample, a single-color IL-2 assay and a single-
color IL-4 assay, and a double-color assay. In the double-
color assay, cells secreting both IL-2 and IL-4 should give
blue-red spots. Due to the strong color of the blue spots, it
was not always easy to distinguish between blue and blue-
red spots, and so multiple methods were used (see Materials
and Methods) to calculate the numbers of cells secreting
only IL-2, only IL-4, or IL-2 plus IL-4 (Fig. 2).
Additional experiments were carried out with the colors
reversed, i.e., red IL-2 spots and blue IL-4 spots (results not
shown). In other experiments, three single-color Elispot as-
says were performed on each sample with anti–IL-2, anti–
IL-4, or combined anti–IL-2 and anti–IL-4 antibodies (re-
sults not shown). By comparing the individual assays with1072 In Vivo Priming of IL-2–producing CD4 T Cells
Figure 1. KLH immunization induced
IL-2 and IL-4, but not IFN-  responses.
Mice were immunized intraperitoneally
with 2.5  g KLH. 7 d later, spleen cells
were restimulated with 80  g KLH in the
Elispot assay. Frequencies of cells secreting
IL-2, IL-4, and IFN-  are expressed as spot
numbers per well (a–c). Solid and open
symbols represent cells with and without re-
stimulation, respectively. Each symbol rep-
resents one of four immunized mice, and X
represents a pool of unimmunized mice
challenged in vitro.  All assays were per-
formed in triplicate, and results are ex-
pressed as mean    SD. IL-2, IL-4, and
IFN-  Elispots of immunized mice (5   105
cells per well) with (d–f) or without (g and
h) KLH restimulation are shown. IFN- 
Elispots from immunized mice (5    105
cells per well) stimulated with ConA are
shown in i.
Figure 2. Many KLH-specific spleen cells
secrete IL-2 but not IL-4 when restimu-
lated. Mice were immunized intraperito-
neally with 2.5  g KLH. 7 d later, spleen
cells were stimulated in Elispot assays with
(a–c) or without (d–f) 80  g/ml KLH.
Spleen cells from unimmunized mice were
also stimulated with KLH (g–i). Single- and
double-color IL-2 and IL-4 Elispot assays
were used to determine the frequencies of
cells secreting IL-2, IL-4, or both IL-2 and
IL-4. M1, M2, and M3 represent three dif-
ferent mice. Frequencies (spots per million
spleen cells) were calculated as described in
Materials and Methods. (a) Cells secreting
only IL-2. Bd, solid bars; Bs-(Rs-Rd),
hatched bars; and Bs-BR, stippled bars. (b)
Cells secreting both IL-2 and IL-4. BR,
solid bars; and Rs-Rd, hatched bars. (c)
Cells secreting only IL-4. Rd, solid bars.1073 Wang and Mosmann
the combined assay, the number of single- and double-pro-
ducing cells could be estimated.
All experiments and calculation methods resulted in the
same conclusions. Large numbers of cells produced IL-2
but not IL-4 or IFN- , and much smaller numbers of cells
secreted either IL-4 or IL-2 plus IL-4. Both IL-2 and IL-4
responses were dependent on immunization with KLH in
vivo and restimulation with KLH in vitro. Cells secreting
both IL-4 and IL-2, but not IFN- , were detected at low
frequencies in this and other experiments (e.g., Fig. 3 bot-
tom). The lack of IFN-  secretion suggests that these were
not Th0 cells (2, 15), but could instead be related to previ-
ously described allospecific T cell clones secreting IL-2, IL-4,
and IL-5 but not IFN-  (2).
Thus by different calculation methods in the first two-
color assay, direct observation of the pure red IL-2 spots in
the second two-color assay, or by the combined results of
single-color assays, we demonstrated that most of the
primed KLH-specific cells secreted IL-2 but not IL-4 or
IFN- .
KLH-specific T Cells Secreting IL-2 but not IL-4 Were
Present for up to 50 d after a Single Immunization. As IL-2–
secreting CD4 T cells can be precursors of Th1 and Th2
cells (18, 19), we considered the possibility that cells pro-
ducing only IL-2 were an intermediate stage during CD4
T cell differentiation, and that the response would eventu-
ally resolve into Th2 and/or Th1 cells. To study the kinet-
ics of the IL-2–secreting T cell response, we immunized
mice with 2.5  g KLH and carried out two-color Elispot
assays 4, 7, 14, 21, or 50 d later to determine IL-2– and
IL-4–producing cells. Both IL-2 and IL-4 responses
peaked 7 d after immunization (Fig. 3). At all time points,
from days 4–50, the majority of KLH-specific cytokine-
secreting cells secreted IL-2 but not IL-4 or IFN- . In this
experiment, the cells secreting only IL-2 made up 75–90%
of the total response, and in additional experiments this
number ranged from  50–90%. The number of double-
producing (IL-2 IL-4 IFN-  ) cells was measured indi-
rectly and is therefore less reliable than the numbers for
the other two populations. However, low numbers of
IL-2  IL-4  IFN-   cells were consistently detected. Cells
producing IL-4 but not IL-2 or IFN-  were also detected
at times up to 50 d. These may represent long-lived, fully
differentiated Th2 cells. No significant antigen-specific
IFN-  response was detected (less than two IFN- –secret-
ing cells per million spleen cells at all time points). Thus,
the cells secreting only IL-2 persist for at least 7 wk after
immunization and so do not appear to be transient inter-
mediates in T cell differentiation.
IL-2–secreting Cells Were Induced by Different Doses of Anti-
gen. Antigen dosage may influence T cell activation and
differentiation by providing different signaling strength
through the T cell receptor (29). To test whether antigen
dosage influenced the induction of IL-2–producing cells,
we measured the frequency of IL-2–producing cells in
mice immunized with 2.5 or 80  g KLH. 7 d after immu-
nization, pooled axillary and popliteal lymphocytes were
restimulated in Elispot assays with 2.5 or 80  g/ml KLH.
Although the frequency of IL-2– or IL-4–producing cells
increased as either the in vivo or in vitro KLH amount in-
creased, the ratio of IL-2– to IL-4–producing cells re-
mained fairly constant (Fig. 4). More directly, two-color
Elispot assays showed cells producing IL-2 but not IL-4 or
IFN-  (represented by pure red spots) constituted the ma-
jority of the IL-2 response in all four combinations of in
vivo and in vitro antigen amounts (Fig. 4).
Ribi Adjuvant Increased the Bias towards Cells Secreting IL-2
but not IL-4. To test the possibility that immunization
with KLH alone may have caused weak responses that
were insufficient to induce T cell differentiation into Th1
or Th2 phenotypes, alternative immunization methods
were used. Immunization with KLH-pulsed dendritic cells
also induced KLH-specific cells secreting IL-2 or IL-4 but
not IFN-  (results not shown). Mice were immunized
with KLH plus Ribi adjuvant, with the expectation that
this would induce more T cell differentiation into effector
cells, particularly Th2 cells, because Ribi adjuvant induces
stronger antibody responses. Addition of Ribi adjuvant to
Figure 3. KLH-specific T cells secreting IL-2 but not IL-4 were
present for up to 50 d after a single immunization. Spleen cells taken from
mice 4, 7, 14, 21, and 50 d after immunization (2.5  g/mouse, intraperi-
toneal) were incubated with or without KLH (80  g/ml) in one- and
two-color Elispot assays. IL-2 IL-4  cells were determined by Bs-(Rs-
Rd); IL-2 IL-4  cells were determined by Rs-Rd; IL-2-IL-4  cells were
determined by Rd (see Materials and Methods). At each time point, data
from each individual mouse is shown. Elispot numbers from unimmu-
nized mice in the presence of KLH stimulation were 3.1, 0.4, and 0 spots
per million spleen cells for IL-2 IL-4 , IL-2 IL-4 , and IL-2 IL-4 
cells, respectively.1074 In Vivo Priming of IL-2–producing CD4 T Cells
the KLH immunization slightly increased the numbers of
IL-2–secreting cells (Fig. 5), but surprisingly, the adjuvant
substantially reduced the numbers of IL-4–secreting cells.
Low numbers of IFN- –secreting cells were detected in
only one mouse. Thus Ribi adjuvant increased the propor-
tion of cells secreting IL-2 but not IL-4 or IFN- , showing
that these cells can be the major antigen-specific population
even during a strong immune response.
Cells Producing only IL-2 Were Detected during Th1-like
Responses. Soluble KLH induced the production of cells se-
creting IL-2 or IL-4, but not IFN- , suggesting a partially
Th2-biased response. We tested whether similar primed IL-
2–producing cells were produced during a Th1-biased re-
sponse by immunizing mice subcutaneously in the neck
with KLH in CFA. After 10 d, cells from the draining
ALNs, nondraining MLNs, and spleen were analyzed by
Elispot. Significant numbers of KLH-specific IFN- –pro-
ducing cells were detected in spleens and ALNs of immu-
nized mice, indicating that a Th1-biased response was in-
duced by this immunization regimen (Fig. 6). IL-2–secreting
cells were present in all three sites, and IL-4–secreting cells
were present mainly in the spleen. To directly show the
presence of cells producing IL-2 in a mixed response that in-
cluded both IL-4 and IFN-  production, we performed
two-color Elispot assays, in which IL-2–producing cells
were identified as red spots and both IL-4 and IFN- –pro-
ducing cells were identified as blue spots. KLH-specific cells
producing IL-2 but not IL-4 or IFN-  were present in
ALNs, MLNs, and spleen, and constituted the great majority
of KLH-specific cells in nondraining MLNs (Fig. 6). Similar
IL-2–secreting T cells were also found in immune responses
against the mycobacterial antigen preparation partially puri-
Figure 4. IL-2–secreting cells were induced by dif-
ferent doses of antigen. Mice were immunized intra-
peritoneally with 2.5  g or 80  g KLH. After 7 d, cells
from ALNs and popliteal LNs were isolated and re-
stimulated in vitro with 2.5 or 80  g/ml KLH in one-
and two-color Elispot assays. Frequencies of cells se-
creting IL-2, IL-4, and IFN-  (one-color assays) or IL-2
but neither IL-4 nor IFN-  (two-color assay) are ex-
pressed as spot numbers per million cells. The bars rep-
resent the average spot number of four mice (each rep-
resented by a different triangle) in each immunization
group. Average background Elispot frequencies with-
out in vitro antigen stimulation were 0.8 (IL-2), 7.9
(IL-4), and 3.3 (IFN- ) per million cells.
Figure 5. Ribi adjuvant biased the immune response towards IL-2 4 
cells. Mice were immunized intraperitoneally with either 2.5  g KLH
alone or 2.5  g KLH plus Ribi adjuvant. 7 d later, spleen cells from three
individual mice for each immunization were stimulated with 80  g/ml
KLH in IL-2, IL-4, and IFN-  Elispot assays. Each group of solid, striped,
and hatched bars represents an individual mouse. Background values
(spots in the absence of antigen) were  23 spots per million spleen cells
and have been subtracted from each value.1075 Wang and Mosmann
fied derivative of Mycobacterium tuberculosis (results not
shown). Thus T cells secreting IL-2 but not IFN-  were
found in responses with a significant Th1 component.
CD4  T Cells Were Responsible for the KLH-specific IL-2
and IL-4 Responses. Although IL-2 production in re-
sponse to exogenous protein immunization is normally due
to CD4 cells, it is also possible to prime CD8 T cells to ex-
ogenous protein antigens (30), and CD8 T cells can also se-
crete IL-2 at moderate levels. To determine the type of
cells producing IL-2 in our experiments, spleen cells from
KLH-immunized mice were depleted of CD4  or CD8 
T cells by magnetic bead separations. KLH-specific IL-2-
and IL-4-producing cells were detected in unseparated and
CD8-depleted spleen cells, but not in either CD4-depleted
or CD4/CD8-depleted cells (Fig. 7). Thus CD4  but not
CD8  cells were required for the IL-2–secreting cell re-
sponse. Sorting of CD4  T cells (e.g., Fig. 8) directly dem-
onstrated that the IL-2–producing cells were CD4  cells.
The IL-2–producing Cells Expressed High Levels of CD44
but not CD25. During an immune response, naive anti-
gen-specific CD4  T cells are activated and induced to dif-
ferentiate into effectors. Various cell surface markers distin-
guish naive from effector and memory cells. CD44
expression is low on naive T cells and high on activated
and memory T cells (31, 32). CD25 (IL-2R ) is expressed
on T cells only transiently after antigen activation (33, 34).
Because the KLH-specific IL-2–producing cells were
primed T cells, we tested whether they had a recently acti-
vated/memory cell phenotype. 7 d after KLH immuniza-
tion, spleen cells were depleted of CD8 , B220 , and
NK1.1  cells, and sorted into three CD4  populations ex-
pressing low, medium, or high levels of CD44. The highest
frequency of IL-2– or IL-4–secreting cells was found in the
CD4 CD44hi population (Fig. 8 a). There were nearly
10,000 IL-2–secreting cells per million CD4 CD44hi cells,
and as this cell population was 5.0% of the unsorted, CD4-
enriched population, this corresponds to 500 IL-2–secret-
ing cells per million unsorted cells, i.e.,  50% recovery of
the activity in the original cells (Fig. 8 b). Negligible num-
bers of KLH-specific cells secreting IL-2 or IL-4 were
found in the CD44med or CD44low populations. In other
experiments, CD44 expression was also high on IL-2–
secreting cells taken 6, 8 d, or 3 mo after immunization with
KLH, or 7 d after immunization with KLH in Ribi adju-
vant (results not shown).
To study CD25 expression, spleen cells from KLH im-
munized mice were depleted of CD8 , B220 , and
NK1.1  cells using magnetic beads, and sorted into
CD4 CD25  and CD4 CD25  populations. 5 d after im-
munization, IL-2–secreting cells were detected at a higher
frequency in the CD4 CD25  population than the
CD4 CD25  population (Fig. 9 a). However, CD25 
cells constituted only 9.2% of the CD4  population, and so
if the Elispot numbers are expressed as a fraction of the un-
sorted cells (Fig. 9 b) the CD4 CD25  cells accounted for
Figure 6. IL-2–producing cells were detected in Th1 responses. Mice
were immunized with 5  g KLH plus CFA subcutaneously in the neck.
After 10 d, (a and b) MLNs (2   105 cells per well), (c and d) ALNs (2  
105cells per well), and (e and f) spleen cells (4   105 per well) from one
unimmunized (a, c, and e) and five immunized (b, d, and f) mice were
stimulated with 80  g/ml KLH in Elispot assays. Frequencies of cells pro-
ducing IL-2, IL-4, and IFN-  were determined in single-color Elispot as-
says. Cells producing IL-2 but not IL-4 or IFN-  were represented by the
frequencies of pure red spots determined in the two-color Elispot assays,
in which IL-2–producing cells were detected as red spots and both IL-4–
and IFN- –producing cells were detected as blue spots.
Figure 7. CD4 T cells were responsible for the KLH-specific IL-2 and
IL-4 responses. Mice were immunized intraperitoneally and/or CD8  T
cells were restimulated with or without 80  g/ml KLH in IL-2, IL-4, and
IFN-  Elispot assays. Background Elispot values from unimmunized mice
with KLH stimulation ranged from 2–10 spots per million spleen cells.1076 In Vivo Priming of IL-2–producing CD4 T Cells
only a small part of the response. After 8 or 11 d, the IL-2–
secreting cells were almost entirely CD25  consistent with
other studies (33, 34).
In Vivo–primed CD4 T Cells Can Differentiate In Vitro into
IL-4– or IFN- –producing Cells. The ability of in vitro–
derived IL-2–producing cells to differentiate into either
Th1 or Th2 cells suggested that if the in vivo–primed IL-
2–producing cells represent a similar phenotype, they
might also be uncommitted precursors of Th1 and Th2
cells. Therefore, we tested the differentiation potential of
the in vivo–primed IL-2–producing cells by split cloning.
CD4 CD44high spleen cells from mice immunized with
KLH plus Ribi were sorted and stimulated with KLH and
irradiated syngenic spleen cells in limiting dilution analysis
(LDA) conditions that included anti–IFN- , anti–IL-4,
and TGF-  to prevent further differentiation. After 5 d,
the wells with growing cells were tested for cytokine se-
cretion in response to KLH by Elispot. Each well that was
 90–95% likely to be clonal (according to the Poisson
equation), and contained cells secreting mainly IL-2, was
split into two aliquots that were restimulated with KLH in
either Th1 or Th2 differentiation conditions. After a fur-
ther 5 d, the differentiation status of the daughter cells
from each split well was determined in IL-2, IL-4, and
IFN-  Elispot assays. A few clones that secreted IL-2 but
not IL-4 or IFN-  after the primary LDA cloning retained
their KLH specificity and became IFN- –producing cells
in Th1 conditions and IL-4–producing cells in Th2 condi-
tions (Fig. 10). This suggests that some in vivo–primed
KLH-specific cells were uncommitted, i.e., they did not
produce IL-4 or IFN-  after the first cycle of growth in
vitro and could differentiate into either Th1- or Th2-like
cells in the second cycle.
Figure 8. The IL-2–producing cells express high levels of CD44. Mice
were immunized intraperitoneally with 2.5  g KLH for 7 d. Spleen cells
were depleted of cells expressing CD8, B220, or NK1.1. The remaining
cells were stained with cychrome-anti-CD4, FITC-anti-CD44, and
PE-anti-CD25 and sorted into CD4 CD25  populations expressing
high, medium, or low levels of CD44 (insert), representing 5.0, 19.4, and
7.5% of the unsorted cells, respectively. The sorted cells were stimulated
with 80  g/ml KLH in Elispot assays. Frequencies of KLH-specific IL-2,
IL-4, and IFN- –secreting cells are expressed as spots per million cells (a)
or per million unsorted cells (b). The background from unimmunized
mice in the presence of KLH was 13 IL-2– and 7 IL-4–secreting cells per
million spleen cells.
Figure 9. CD25 expression on cells secreting IL-2. Mice were immu-
nized intraperitoneally with 2.5  g KLH for 5, 8, or 11 d. Spleen cells
were depleted of CD8 , B220 , and NK1.1  cells, stained with cy-
chrome-anti-CD4 and PE-anti-CD25, and sorted into two populations:
CD4 CD25  and CD4 CD25  (insert). The sorted cells were stimulated
with 80  g/ml KLH in Elispot assays. The frequencies of KLH-specific
IL-2–producing cells are expressed as spots per million cells (a) or per mil-
lion unsorted cells (b). The background from unimmunized mice in the
presence of KLH was 1.7 IL-2–secreting cells per million spleen cells.1077 Wang and Mosmann
Many TCR Transgenic Cells Primed In Vivo Are Uncommit-
ted and Can Differentiate into either IL-4– or IFN- –producing
Cells. Although the split-cloning LDA experiments dem-
onstrated that IL-4– or IFN- –producing cells were de-
rived from in vivo–primed cells that did not initially pro-
duce either cytokine in vitro, the uncertainty of clonality
meant that these experiments could not unambiguously
prove that both Th1- and Th2-like cells were derived from
a single primed precursor. To resolve this uncertainty, the
differentiation potential of IL-2–producing cells was further
investigated using DO11.10 C  /  TCR transgenic mice.
Using the clonotypic antibody KJ1-26, individual DO11.10
cells could be directly isolated for cloning by direct deposi-
tion using a Coulter Elite FACS®, i.e., each well contained
one cell with no statistical uncertainty.
Pooled spleen and LN cells of naive DO11.10 C  / 
TCR transgenic mice were adoptively transferred into na-
ive Balb/c mice, which were then immunized subcutane-
ously in the neck with the OVA peptide323–339 (POVA) rec-
ognized by the DO11.10 transgenic TCR plus Ribi
adjuvant. In preliminary experiments, immunization in-
creased the frequency of KJ1-26  transgenic CD4 T cells
in the ALNs (7.0 versus 1.0% in unimmunized mice), and
the mean fluorescence intensity of CD62L expression on
the transgenic T cells decreased from 678 to 93, suggesting
that the transgenic T cells had been efficiently primed by
immunization. Fig. 11 a shows that 6 d DO11.10-injected
mice were immunized with POVA, many POVA–specific cells
in the ALNs secreted IL-2 or IFN-  but not IL-4, suggest-
ing that a Th1-biased response was induced. Single
CD62L  KJ1-26  CD4  cells from the ALNs of immu-
nized host mice were sorted into 96-well plates and stimu-
lated with antigen and APCs in the presence of anti–IFN- ,
anti–IL-4, and TGF- , conditions that maintain an un-
committed phenotype during in vitro culture (18). After 10 d,
aliquots of cells from each growing clone were restimu-
lated in IL-2, IL-4, and IFN-  Elispot assays before split-
ting to determine the differentiation status of the clones
(Fig. 11 b). Of the 146 clones derived from the first clon-
ing, 111 clones contained a significant number of cytokine-
producing cells (at least 10 IL-2, IL-4, or IFN-  spots). 60
of these 111 clones produced IL-2 but not IL-4 or IFN- .
Each clone was then split into two aliquots, which were
restimulated in either Th1 or Th2 differentiation condi-
tions. After 5 d, the cytokine secretion phenotype of each
split clone was determined by Elispot assay (Fig. 11 c). All
clones that produced IL-2 and IFN-  after the initial cycle
in vitro (i.e., committed Th1 clones) also produced IFN- 
after the second cycle, regardless of whether they were cul-
tured in Th1- or Th2-inducing conditions (e.g., Fig. 11 c,
Figure 10. Uncommitted KLH-specific IL-2–producing cells revealed
by LDA. C57Bl/6 mice were immunized intraperitoneally with 2.5  g
KLH plus Ribi adjuvant. 7 d later, spleen cells were stained with cy-
chrome-anti-CD4, FITC-anti-CD44, PE-anti-CD8, and PE-anti B220.
CD4 CD44highCD8 B220  cells were sorted and stimulated with 100
 g/ml KLH and APCs in LDA plates, in the presence of anti–IFN- ,
anti–IL-4, TGF- , IL-7, and IL-2. After 6 d, positive growing wells were
picked and restimulated with KLH in Th1 conditions with IL-2, IL-7,
IL-12, and 11B11, or Th2 conditions with IL-2, IL-7, IL-4, and
XMG1.2 for another 4 d. Cells were then washed and rested in medium
with only IL-2. 2 d later, they were restimulated with KLH in an Elispot
assay to measure the frequencies of IL-2–, IL-4–, and IFN- –producing
cells. The probability that each well initially contained a single KLH-spe-
cific T cell was 90% (well C9) and 95% (well E6).
Figure 11. In vivo–primed DO11.10 cells secreting only IL-2 can dif-
ferentiate into IL-4 and IFN- –producing cells. Balb/c mice were immu-
nized with 25  g OVA peptide plus Ribi adjuvant subcutaneously in the
neck. 6 d later, cells from the ALNs were restimulated with 2  g/ml
OVA peptide in IL-2, IL-4, and IFN-  Elispot assays (a). The cells were also
stained with cychrome-anti-CD4, biotinylated-KJ1-26, PE-anti-CD62L,
and FITC-streptavidin for autoclone sorting. Single CD4 CD62lowKJ1-26 
cells were stimulated with 2  g/ml OVA peptide and 104 TA3 cells in the
presence of IL-2, IL-7, anti–IFN- , and anti–IL-4. 7 d later, IL-2–, IL-4–,
and IFN- –producing cell frequencies were determined in Elispot assays
by stimulating with 2  g/ml OVA peptide and 4   105 Balb/c whole
spleen cells per well (b). Aliquots of cells from each growing clone were
then restimulated in Th1 or Th2 conditions with 2  g/ml OVA peptide
and 104 TA3 cells for 5 d, followed by IL-4 and IFN-  Elispot assays of
the split clones (c).1078 In Vivo Priming of IL-2–producing CD4 T Cells
clone F3). Of the 54 IL-2–producing cell clones that grew
in the second cycle, 27 of these (e.g., Fig. 11 c, clones C4,
Ex-2, E12) were judged to be initially uncommitted be-
cause these clones secreted only IL-2 after the first cycle of
growth in vitro; the majority of the spot-forming cells se-
creted IFN-  after growth in Th1 conditions; and the ma-
jority secreted IL-4 after growth in Th2 conditions. This
demonstrated that in vivo priming induced a substantial
proportion of IL-2–producing cells that were uncommitted
precursors that could further differentiate into Th1 and
Th2 effector cells in the appropriate conditions.
Discussion
When first stimulated by antigen in tissue culture, naive
T cells normally differentiate into effector phenotypes such
as Th1 or Th2, particularly with the addition of IL-12 or
IL-4. However, in the current studies we examined the
phenotypes of T cells produced during an in vivo response
and found that many antigen-primed T cells are uncom-
mitted precursor cells that secreted IL-2 but not IL-4 or
IFN- . This phenotype is similar to the proliferating pre-
cursor cells derived in vitro by stimulating naive mouse
CD4 T cells with alloantigens in the presence of TGF- 
and anti–IFN-  (18), although the exact equivalence of
the in vitro and in vivo primed precursor cells has not yet
been established.
Several lines of evidence suggest that the primed IL-2–
secreting cells are not a transient intermediate stage during
T cell differentiation. Previous studies have shown that
memory T cells produce relatively high levels of IL-2 and
lower levels of IL-4 or IFN-  (2, 32). In our experiments,
the frequency of cells secreting IL-2 remained at a rela-
tively high level even 50 d after immunization with a low
amount of soluble antigen. Although we expected that
Ribi adjuvant would induce a stronger response and there-
fore cause more T cells to fully differentiate into effector
cells (e.g., Th2), this adjuvant actually increased the pro-
portion of cells secreting IL-2 but not IL-4 or IFN- . Im-
munization of mice with antigen plus CFA induced a Th1-
biased response with both IL-2- and IFN- –producing
cells in the spleen and draining LNs. Although cells pro-
ducing only IL-2 could have been Th1 cells that failed to
produce IFN-  on that particular occasion (12, 35), the IL-
2–secreting cells were much more abundant than IFN- –
secreting cells in the nondraining LNs, and the cloning ex-
periments with TCR transgenic T cells (Fig. 11) confirmed
that uncommitted IL-2–secreting cells could be induced
during Th1-biased responses. Taken together, these results
suggest that the IL-2–producing cells are not a transient T
cell population, but can survive for a long time and consti-
tute an important part of the memory T cell reservoir.
Do the IL-2–producing cells secrete any other cyto-
kines? The two-color Elispot results, and the Ribi adjuvant
experiments, showed clearly that the majority of IL-2–
secreting cells did not secrete either IL-4 or IFN- . Al-
though some single-cell methods analyzing cytokine pro-
duction at one time point (in situ hybridization,
intracellular staining) have suggested that even T cell clones
do not always express cytokines coordinately (8, 35), the
Elispot method detects cytokine secretion over a longer pe-
riod and so should be less subject to this reservation. Also,
no IFN- –secreting cells were detected in most KLH-immu-
nized populations, so the large excess of IL-2–secreting
cells in all of our experiments strongly suggests that the IL-
2–secreting cells are not just Th1 cells that did not secrete
IFN-  on that particular occasion. Even after immuniza-
tion with partially purified derivative of Mycobacterium tuber-
culosis  or KLH plus Ribi adjuvant, which induced low
numbers of IFN- –secreting cells, the great majority of the
antigen-specific cytokine-secreting cells were IL-2 IL-4 
IFN-g . In preliminary experiments, we have also tested
the antigen-specific secretion of IL-3, IL-5, and IL-6, and
found that most of the IL-2–secreting cells did not secrete
any of these cytokines (results not shown). Thus, the IL-2–
secreting cells appear to secrete few if any of the character-
istic Th1 or Th2 cytokines.
We have shown that IL-2–secreting cells primed in vitro
(18) or in vivo (this study) are uncommitted, and can dif-
ferentiate into either Th1 or Th2 cells. An analysis of hu-
man peripheral blood T cells revealed a subpopulation that
may be the human equivalent (24) of the long-term primed
IL-2–secreting mouse T cells that we have identified.
These human T cells were CCR7high CD45RAlow and se-
creted high levels of IL-2 and low levels of IFN-  when
stimulated. After 10 d of stimulation in vitro, a substantial
number of cells secreted IFN-  and had lost expression of
CCR7, suggesting that some of the CCR7  cells could
differentiate or selectively proliferate. The human CCR7 
IL-2–producing cells were found at long times after immu-
nization, consistent with our data from mice immunized
for 50 d.
Primed, IL-2–producing cells show different distribution
patterns from effector cells. The expression of CCR7 and
CD62L on the human IL-2–producing memory cells sug-
gests that they home preferentially to LNs (24). A LN pop-
ulation of mouse memory CD4 T cells generated in vivo
by antigen plus LPS immunization secreted only IL-2, in
contrast to the secretion of both IL-2 and IFN-  by T cells
from nonlymphoid tissue (23). In addition, mouse IL-2–
producing cells generated in vitro by a short antigenic stim-
ulation (21) home mainly to LNs but not to spleen and
other peripheral tissues, in contrast to polarized Th1 and
Th2 cells. Together with our observation that the in vivo–
primed IL-2–producing cells were enriched in nondraining
LNs (Fig. 6), this suggests that the primed, uncommitted
cells circulate preferentially through LNs, whereas effector
T cells mainly enter the spleen and nonlymphoid tissues.
What conditions are required in vivo for the mainte-
nance of these IL-2–producing cells? TGF-  (or anti–IL-4)
and anti–IFN-  are required for the maintenance of similar
IL-2–producing cells in vitro, (18, 19). TGF-  is produced
by several cell types (36) and so may also influence T cell
differentiation in vivo, and the cytokine antagonist func-
tions may be supplied by soluble receptors instead of anti-1079 Wang and Mosmann
bodies. Alternatively, IL-4, IL-12, and IFN-  may exist at
such low concentrations in some locations that T cells do
not receive sufficient signals to induce differentiation and
therefore remain as IL-2–secreting cells. Brief antigen stim-
ulation also induced a similar population of primed, IL-2–
producing cells (21). Finally, it is possible that there are ad-
ditional costimulatory or cytokine signals that maintain
primed cells in an undifferentiated state.
The primed IL-2–producing CD4 T cells comprise the
majority of some immune responses, even with strong ad-
juvants. The IL-2 may cause optimal proliferation of these
cells, resulting in rapid expansion of the antigen-specific
population. These primed, bipotential CD4 T cells might
provide an expanded population of uncommitted antigen-
specific precursor T cells that could include both recently
activated and memory cells, as IL-2–producing T cells
comprised the majority of KLH-specific cells for at least 50 d
after immunization. Preferential migration of these cells
into LNs during an immune response should provide an
ideal environment for future reeducation and differentia-
tion according to APC signals. Even if an appropriate im-
mune response was mounted during the priming infection,
the effector phenotype required during a secondary re-
sponse might be different if the secondary infection in-
volved a cross-reactive pathogen that was best attacked by
different effector mechanisms. Thus, the induction of a
substantial population of primed, uncommitted cells would
give more flexibility for subsequent differentiation into
Th1, Th2, or other phenotypes, allowing a more appropri-
ate reaction to future infections.
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